Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations

Key Points

• To evaluate the long-term efficacy and safety of opicapone as an add-on to levodopa in Parkinson's patients without motor fluctuations.
• Conducted a 24-week double-blind study followed by a 1-year open-label treatment for eligible participants.
• Compared motor impairment outcomes in patients receiving opicapone versus placebo during the double-blind phase.
• Utilized the MDS-UPDRS motor score to assess symptomatic efficacy over the study duration.
• Adding opicapone significantly improved motor impairment without increasing motor complications compared to placebo.
• After 1 year, motor scores improved by −7.4 from baseline in the opicapone group, while those switching from placebo saw a −6.1 improvement.
• 80.2% of opicapone-treated participants remained free of motor complications at Week 76, compared to 69.7% in the placebo group.